PMID- 16997310
OWN - NLM
STAT- MEDLINE
DCOM- 20071227
LR  - 20131121
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 194
IP  - 2
DP  - 2007 Oct
TI  - Reduced systemic inflammatory response to implantation of sirolimus-eluting 
      stents in patients with stable coronary artery disease.
PG  - 433-8
AB  - Stent implantation causes significant injury to the vascular wall, resulting in 
      inflammatory activation. Although sirolimus-eluting stents (SES) have 
      anti-inflammatory properties, their effect on periprocedural systemic 
      inflammatory response has not been sufficiently investigated. Eighty-one patients 
      with stable coronary artery disease involving severe stenosis of one major 
      epicardial coronary artery underwent coronary angioplasty with stent implantation 
      and randomly received either SES or bare metal stents (BMS). Blood samples were 
      taken 24h before, at 24h, 48 h and 1 month after the angioplasty and levels of 
      high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin-1 
      beta (IL-1 beta), and monocyte chemoattractant protein-1 (MCP-1) were determined. 
      HsCRP after BMS implantation increased over 24h (p<0.001) and then remained 
      steady, as did IL-6 and IL-1 beta similarly. In contrast, their levels in SES 
      patients decreased to below baseline by the end of the month. MCP-1 levels 
      increased by the end of 1 month (p<0.001) in the BMS group, whereas in SES they 
      steadily decreased, becoming significantly lower than baseline from 48 h 
      (p=0.015). In conclusion, patients with SES exhibit an attenuation of the 
      postprocedural systemic inflammatory activation during a 1-month follow-up after 
      stent implantation. This might partially explain the reduced restenosis rate 
      associated with SES.
FAU - Kochiadakis, George E
AU  - Kochiadakis GE
AD  - Cardiology Department, University Hospital of Heraklion, Heraklion, Crete, 
      Greece.
FAU - Marketou, Maria E
AU  - Marketou ME
FAU - Arfanakis, Dimitris A
AU  - Arfanakis DA
FAU - Sfiridaki, Katerina
AU  - Sfiridaki K
FAU - Skalidis, Emmanuel I
AU  - Skalidis EI
FAU - Igoumenidis, Nikos E
AU  - Igoumenidis NE
FAU - Hamilos, Michael I
AU  - Hamilos MI
FAU - Kolyvaki, Stavroula
AU  - Kolyvaki S
FAU - Chlouverakis, Gregory
AU  - Chlouverakis G
FAU - Kantidaki, Ermioni
AU  - Kantidaki E
FAU - Castanas, Elias
AU  - Castanas E
FAU - Vardas, Panos E
AU  - Vardas PE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20060925
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - C-Reactive Protein/drug effects
MH  - Chemokine CCL2/drug effects
MH  - Coronary Artery Disease/*drug therapy/immunology
MH  - *Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage/immunology
MH  - Inflammation/drug therapy
MH  - Interleukin-1beta/drug effects
MH  - Interleukin-6/blood
MH  - Male
MH  - Middle Aged
MH  - Sirolimus/*administration & dosage/immunology
EDAT- 2006/09/26 09:00
MHDA- 2007/12/28 09:00
CRDT- 2006/09/26 09:00
PHST- 2006/03/24 00:00 [received]
PHST- 2006/08/09 00:00 [revised]
PHST- 2006/08/14 00:00 [accepted]
PHST- 2006/09/26 09:00 [pubmed]
PHST- 2007/12/28 09:00 [medline]
PHST- 2006/09/26 09:00 [entrez]
AID - S0021-9150(06)00489-8 [pii]
AID - 10.1016/j.atherosclerosis.2006.08.029 [doi]
PST - ppublish
SO  - Atherosclerosis. 2007 Oct;194(2):433-8. doi: 
      10.1016/j.atherosclerosis.2006.08.029. Epub 2006 Sep 25.